Novartis said on Tuesday that its multiple sclerosis pill remibrutinib cut relapse rates significantly more than teriflunomide, an established oral treatment, in two large Phase III trials. The Swiss drugmaker reported no liver safety signal, the problem that has held back rival drugs in the same class.
Two Trials, One Clear Result
The Basel-based group published topline results from the REMODEL-1 and REMODEL-2 studies early on 1 September in an ad hoc announcement, the disclosure Swiss listing rules require for price-sensitive news. The two identical trials enrolled about 2,000 adults with relapsing multiple sclerosis and recent disease activity, assigned in equal numbers to remibrutinib 100 mg or teriflunomide, the drug Sanofi sells as Aubagio.
Both studies met their primary endpoint, a significant reduction in the annualised relapse rate against teriflunomide. Novartis said remibrutinib was also superior on all key secondary endpoints in each trial, including the number of new or enlarging lesions seen on MRI brain scans. Patients were followed in a double-blind core phase of up to 30 months, with an open-label extension of up to five years.
On disability, the results were less clear-cut. A preplanned combined analysis of the two trials showed a positive trend in disability progression confirmed after three months, and nominal significance for progression confirmed after six months. Novartis described the effect as clinically meaningful but did not publish relapse rates, lesion counts or other figures.
What Novartis reported
- Both Phase III trials met the main goal: fewer relapses per year than on teriflunomide
- Superior on key secondary endpoints in each trial, including MRI lesions
- Disability: positive trend at three months, nominal significance at six months, in pooled data
- No liver safety signal and no cases meeting Hy's Law criteria
- Plans to seek approval in relapsing MS worldwide; detailed data due at MSToronto2026
Novartis: share price, chart and news

The Liver Question Hanging Over BTK Drugs
Remibrutinib belongs to a class of medicines that block Bruton's tyrosine kinase, or BTK, an enzyme involved in the immune cells thought to drive damage in multiple sclerosis. The class has been one of the most closely watched areas of neurology, and also one of the most troubled.
Sanofi's tolebrutinib missed its goals in relapsing MS, looked more effective in a less common progressive form of the disease, and was rejected in the United States before winning approval in Europe in June. Merck KGaA's evobrutinib stumbled in testing. Liver-related side effects slowed both programmes, and analysts have questioned whether regulators will approve Roche's fenebrutinib for the same reason.
That is why the safety line in Tuesday's statement matters as much as the efficacy result. Novartis said the drug was well tolerated, that safety was consistent with a development programme covering more than 4,500 trial participants, and that there were no cases meeting Hy's Law criteria, the standard regulators use to flag a drug's potential to cause serious liver injury.
Already on the Market for Chronic Hives
Remibrutinib is not new to regulators. A 25 mg dose is approved under the brand name Rhapsido for chronic spontaneous urticaria, a long-lasting form of hives. The US Food and Drug Administration cleared it in September 2025 and European approval followed in April 2026, according to Novartis.
The multiple sclerosis trials used a higher 100 mg dose, so the earlier approvals do not settle the question on their own. But Novartis says the whole remibrutinib programme, now including roughly 2,000 MS patients in trials with a blinded phase of up to 30 months, has shown no liver safety signal. If the detailed data bear that out, it would be a stronger safety case than its rivals have been able to make.
Novartis already has a large presence in multiple sclerosis. An oral drug that beat an established pill on relapses in two trials, and that avoids the liver problems seen elsewhere in its class, would give the company a new product in a market where patients and doctors weigh convenience against efficacy.
What Happens Next
Novartis said it plans to file for approval of remibrutinib in relapsing multiple sclerosis around the world. Detailed results will be presented as a late-breaking abstract at the MSToronto2026 congress, and the company intends to host an investor call after that presentation.
Those numbers will decide how the drug is positioned. The size of the relapse reduction against teriflunomide, the strength of the disability data and the full liver safety tables are what doctors, regulators and investors will scrutinise, because teriflunomide is an older, moderate-efficacy pill rather than one of the antibody therapies used for more active disease.
For now, the read-across for the sector is twofold: Novartis has a credible new growth driver in neurology, and the pressure on rival BTK programmes to show comparable liver safety has increased.








